Insulet Corporation filings document the financial, regulatory, governance, and operating disclosures of a medical device company built around the Omnipod tubeless insulin delivery platform. Current reports record quarterly and annual results, Omnipod revenue categories, U.S. and international performance, drug delivery revenue, and related financial-condition disclosures.
Insulet’s SEC filings also cover Regulation FD updates on product-quality and medical device correction matters, material supply agreements, stock repurchase authorizations, executive severance arrangements, auditor changes, and proxy governance. Its definitive proxy materials describe board oversight, executive compensation, leadership structure, and other shareholder-voting matters tied to the company’s public-company governance.
INSULET CORP senior vice president Laetitia Cousin reported equity compensation and related tax withholding transactions. She received an annual grant of 1,044 shares of common stock as restricted stock units that vest in three substantially equal installments on the first, second and third anniversaries of the grant date.
She also received an annual non-qualified stock option award for 2,718 shares that becomes exercisable in four substantially equal installments on each of the first four anniversaries of the grant date. In a separate transaction, 111 shares of common stock were withheld at a price of $248.12 per share to cover tax obligations upon RSU vesting.
Insulet Corp Group VP, CAO and Controller Lauren Budden reported routine equity compensation transactions. She received a grant of 611 shares of common stock and an option for 1,591 shares, both at a grant price of $0.00 per share, reflecting stock-based awards rather than open‑market activity.
To cover taxes on vested restricted stock units, 55 shares of common stock were withheld at a price of $248.12 per share, characterized as a tax-withholding disposition. Following these transactions, she directly owned 8,744 common shares and held an option for 1,591 shares, with vesting and exercisability occurring in installments over several years.
INSULET CORP senior vice president and general counsel John W. Kapples reported routine equity compensation and related tax withholding transactions. On February 24, he received an annual grant of 1,885 shares of common stock as restricted stock units that vest in three equal installments and settle one-for-one in common shares. He also received an annual non-qualified stock option award for 4,907 shares, which becomes exercisable in four equal installments over four years. On February 25, 263 shares of common stock were withheld at a price of $248.12 per share to cover tax obligations from vesting RSUs, rather than sold in the open market. After these transactions, he directly held 28,119 shares of common stock and 4,907 stock options.
Insulet Corp EVP and COO Benjamin Eric reported a mix of equity awards and share withholding transactions. He received a grant of 3,822 shares of common stock as an annual restricted stock unit award, which will vest in three equal installments on the first, second, and third anniversaries of the grant date. He was also granted 9,946 non-qualified stock options that become exercisable in four equal installments on each of the first four anniversaries of the grant date.
In a separate transaction, 395 shares of common stock were withheld at a price of $248.12 per share to cover tax obligations arising from RSU vesting, reducing his directly held common stock to 24,512 shares after the withholding.
Insulet Corp reported equity awards to senior executive Lisa Blair Davis, the SVP and Chief HR Officer. She received an annual grant of 5,570 employee stock options with an exercise schedule vesting in substantially equal installments over four years from the grant date of February 24, 2026.
On the same date, she was also granted 2,140 restricted stock units (RSUs), which vest in substantially equal installments over three years and settle into common shares on a one-for-one basis. After these grants, she directly owns 4,617 shares of common stock.
INSULET CORP executive Flavia Pease received new equity awards. On the reported date, the EVP & CFO was granted 3,822 shares of common stock and an employee stock option for 9,946 shares at an exercise price of $0.0000 per share.
The 3,822-share grant is an annual restricted stock unit award that vests in substantially equal installments on each of the first, second and third anniversaries of the grant date and settles one-for-one in common stock. The 9,946-share non-qualified stock option becomes exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date.
INSULET CORP President and CEO Ashley McEvoy received new equity awards. On February 24, 2026, McEvoy was granted an option to buy 26,143 shares of common stock at an exercise price of $0.00 per share and an award of 10,046 restricted stock units.
The option award becomes exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date. The restricted stock units vest in substantially equal installments on each of the first, second and third anniversaries and are settled one-for-one in common shares. Following these awards, McEvoy directly holds 23,962 common shares, with an additional 4 shares held indirectly through a trust.
INSULET CORP director-related trust buys additional shares. On February 25, 2026, a trust associated with director Michael R. Minogue purchased 2,030 shares of Insulet common stock in open-market transactions at a weighted average price of $246.23 per share. After this, the trust held 17,483 shares indirectly, while Minogue also held 778 shares directly.
Insulet Corporation is amending a prior report to confirm that Grant Thornton LLP has completed its audit of the company’s consolidated financial statements for the fiscal year ended December 31, 2025 and has now been dismissed as independent auditor. PricewaterhouseCoopers LLP was previously selected as Insulet’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and that appointment did not affect Grant Thornton’s 2025 engagement.
Grant Thornton’s reports on the company’s 2025 and 2024 financial statements contained no adverse opinions, disclaimers of opinion, or qualifications as to uncertainty, audit scope, or accounting principles. The company states there were no disagreements or reportable events with Grant Thornton through February 18, 2026, and that it did not consult PwC on specific accounting matters, potential audit opinions, disagreements, or reportable events during 2024, 2025, or the subsequent interim period.
Insulet Corp President and CEO Ashley McEvoy reported an open-market purchase of 4,300 shares of common stock on February 20, 2026 at a weighted average price of $239.35 per share. After this transaction, McEvoy directly owned 13,916 common shares, with an additional 4 shares held indirectly by a trust.
The filing notes that these 4,300 shares were bought in multiple trades at prices ranging from $238.55 to $241.56, with specified weighted average prices for each price band.